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therapy months ranged from $452–$921 for discontinued
patients and from $423–$483 for non-switched, contin-
ued patients. CONCLUSIONS: Patients who discontinued
SSRI therapy early tended to have higher costs than pa-
tients who continued therapy. It is unclear whether these
increased costs stem from treatment of medication side
effects or increased utilization related to lack of efficacy
of the initial antidepressant. Alternatively, early switchers
may simply be more clinically complex patients.
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OBJECTIVES: In France a large part of acute hospitalisa-
tion beds are occupied by long-term hospitalisation of
schizophrenic patients. A model was developed to com-
pare Intensive Case Management (ICM) to Standard Case
Management (SCM) for long-term hospitalised chronic
schizophrenic patients. METHODS: A model was used
to evaluate the number of patients that are either success-
fully dechronized, experiencing failure, or are readmitted
to hospital within a year for a cohort of 100 chronic
schizophrenic patients. With these figures, it was possible
to estimate the needs in terms of number of beds and em-
ployees in the catchment area of Clermont-Ferrand in
France, for the 1st, 2nd and 3rd year after the ICM strat-
egy have been implemented. RESULTS: At the beginning
of the first year, 100 hospitalisation beds, 30 nurses, 10
psychologists and 5 psychiatrists were needed. After 1
year these numbers were respectively reduced to 50, 15,
10 and 2.5 due to the success of the ICM strategy. This
positive trend is also recorded for the second year of im-
plementation. At the end of the 3rd year a steady point
level is nevertheless reached with the model, due to the
fact that there will always be patients that can not be
dechronized; the numbers at this point will be 11 beds, 3
nurses, 1 psychologist and a half-time psychiatrist. CON-
CLUSIONS: Due to the important caseload of ICM, it re-
mains more costly than SCM at implementation, but will
reduce cost from year 1, and be less costly than SCM
from year 3. This model can therefore evaluate the eco-
nomic impact of creating a dechronization unit in a
catchment area and make budgetary prevision for large-
scale implementation of ICM in France.
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BACKGROUND: It has been reported that approxi-
mately 1% of young women have anorexia nervosa and
4% bulimia. Managing eating disorders requires a multi-
disciplinary approach including acute hospitalization,
when necessary. This study was undertaken to assess the
cost of acute hospital care for these disorders. METH-
ODS: Inpatient cost estimates, adjusted for medical infla-
tion and cost-to-charge ratios, were developed using data
from all-payer 1998 discharge databases from five states,
supplemented with national fee schedules. ICD9 codes
were used to identify those with a principal diagnosis of
anorexia (307.1) or bulimia (307.51). Cases where both
diagnoses were coded are excluded from results reported
here. Log transformation was used to address highly
skewed distributions. Length-of-stay (LOS), disposition
and psychiatric unit care (PSYU) were also examined.
Hospital costs (i.e., accommodation, ancillary, physician)
are reported in 2000 US$. RESULTS: The state databases
yielded 641 cases of anorexia and 326 of bulimia. The
overwhelming majority (96%) were females. For anor-
exia: the mean age was 25 years (45% 20 years); mean
LOS was 13; 24% received care in a PSYU; 87% were
discharged home; 7% went to a rehab or mental health
facility (MHF) and 3% left against medical advice
(AMA). For bulimia, the mean age was 27 years (25%
20 years); mean LOS was 9; 39% received care in a
PSYU; 90% were discharged home; 4% to rehab or
MHF; 3% left AMA. The mean total cost per hospital
stay was $12,390 for anorexia and $9,120 for bulimia.
On average, the number of annual admissions was 1.6
and 1.2 for anorexia and bulimia, respectively. Managed
care was the largest primary payer. CONCLUSIONS: Al-
though hospitalization is not the primary site of medical
care for managing serious eating disorders, it’s sometimes
required. We believe that this information provides an es-
sential piece in understanding the economic consequences
of these conditions.
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OBJECTIVE: To estimate and compare the efficacy,
treatment-emergent adverse events, costs and outcomes
of olanzapine and ziprasidone for treatment of schizo-
phrenia. METHODS: A decision-analytic model was
used to determine outcomes for patients treated over a
1-year period. Model parameters were based on clinical
trial data and published medical literature. Data from
different trials were compared only when patient popula-
tions were similar. Comparative studies were available
for weight gain and cardiovascular events. For essential
parameters with no relevant study results, assumptions
were made that the medications would be similar. RE-
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SULTS: Compared to patients treated with ziprasidone,
data seem to suggest that olanzapine patients had a
higher response rate, a higher incidence of weight gain,
and a lower incidence of QTc prolongation. Total medi-
cal cost was higher for ziprasidone patients when the
medication cost of ziprasidone was assumed to be more
than half the price than that of olanzapine. The olanza-
pine group’s costs were more sensitive to changes in drug
costs, whereas the ziprasidone group’s costs were more
sensitive to the response rate of the medication used for
those patients not responsive to ziprasidone. CONCLU-
SIONS: Compared to ziprasidone patients, olanzapine
patients may have a higher response rate, a higher inci-
dence of weight gain, and a lower incidence of QTc pro-
longation, with lower total costs as long as ziprasidone is
more than half the price of olanzapine.
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OBJECTIVES: We report on trends in medication adher-
ence for patients who received conventional and atypical
antipsychotics under routine outpatient care during a
9-month period in 1998–9. METHODS: Refill records
were analyzed for over 25,000 patients at a national re-
tail pharmacy chain. Persistence was defined as a pa-
tient’s possession of medication at 30 day intervals from
a patient’s initial prescription. Persistence was taken as a
proxy for medication adherence. RESULTS: The percent-
age of patients adhering to therapy at nine months was
44.4% for atypical agents; 47.6% for conventional
agents; and 71.1% for clozapine. CONCLUSIONS: Im-
proved clozapine adherence was associated with a closely
supervised medication administration process that en-
sured patient tracking and frequent and sustained pa-
tient-provider contact. Atypical agents, with their im-
proved side-effect profile relative to conventional agents,
were not associated with better adherence. These results
suggest that improved side-effect profiles alone may not
insure higher levels of medication adherence and that im-
proved medication administration processes may facili-
tate higher levels of outpatient medication adherence for
patients with major mental illness.
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OBJECTIVE: Comparative cost-effectiveness was as-
sessed in an open-label, randomized trial (QUEST) that
compared the efficacy and safety of quetiapine with ris-
peridone in a outpatient population with schizophrenia
or other psychotic disorders. METHOD: Based on the
overall Positive And Negative Syndrome Scale (PANSS)
scores, patients in QUEST were categorized into one of
three health states—mild (PANSS 74.5), moderate
(PANSS 74.5 and 106.5), or severe (PANSS score
106.5)—at baseline and at 2 months and 4 months.
Utilities and expected utilities from baseline were calcu-
lated. RESULTS: At baseline, 297 (54.0%), 206 (37.5%),
and 47 (8.5%) quetiapine patients, had mild, moderate
or severe symptoms compared to 102 (59.0%), 55
(31.8%), and 16 (9.2%) in the risperidone group. For pa-
tients in the mild or moderate states at baseline, improve-
ments were seen in both treatment groups. For severe pa-
tients, more quetiapine patients improved: 21.2% versus
7.7% in the mild state and 60.6% versus 30.8% in the
moderate state (p  0.020) at 2 months and 46.9% ver-
sus 0.0% in the mild state and 40.6% versus 62.5% in
the moderate state (p  0.023) at 4 months. Overall,
when weighted by utilities, quetiapine treated patients at-
tained greater gains in health state utilities at each follow-
up visit for the mild (0.61  0.069), moderate (0.36 
0.073) and severe (0.29  0.071) states. At 2-months,
quetiapine patients enjoyed a gain of 0.239 from their
baseline level compared to 0.175 for the risperidone
group. At 4-months, the gains were 0.329 versus 0.184
for the quetiapine and risperidone groups (p  0.05). Av-
erage daily doses were 253.9mg quetiapine and 4.4mg
risperidone, yielding average daily costs to US consumers
of $6.38 and $7.85. At average retail costs to consumers
in the US, quetiapine reduces costs by $1.47/day or
$536.55 annually. CONCLUSION: Patients with schizo-
phrenia or other psychotic disorders, treatment with que-
tiapine resulted in significant effectiveness and cost sav-
ings compared with risperidone.
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CONTEXT: So-called chronic depression, a limiting fac-
tor in terms of social reinsertion, must be diagnosed to
enable its management and to prevent a decline towards
a profound, desocialised state. OBJECTIVE: To deter-
mine the incidence of depression in populations of the
homeless, who are users of the Samu Social de Paris—
Paris Social Emergencies Unit—(SSP). METHOD: Once
an individual had been assessed and a response found to
his or her need, it was suggested that patients calling the
SSP free-phone number should agree to complete the
CES-D questionnaire. Developed in the US by Randloff
(1977), this questionnaire enables the detection of de-
pressive symptoms in a given population. Its use over the
